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Abstract
Recent studies have indentified imidazole-dioxolane based compounds as novel heme oxyenase
(HO) inhibitors. While these compounds have been demonstrated to be specific HO inhibitors in
vitro, they have yet to be used to inhibit renal HO activity in vivo. The goal of this study was to
determine the effectiveness of the imidazole-dioxolane HO-1 inhibitor, QC-13, in the inhibition of
renal HO activity in vivo. HO-1 was induced in mice by treatment with cobalt protoporphyrin
(CoPP). After 5 days, QC-13 was delivered either by continuous intrarenal medullay interstitial
infusion (IRMI) into one kidney at several concentrations for 72 hours or by two intraperitoneal
injections over a 48 hour period. IRMI infusion of QC-13 at a concentration of 25 μM resulted in a
significant decrease in medullary but not cortical HO activity as compared to CoPP treated
kidneys. IRMI infusion of QC-13 at a lower concentration (2.5 μM) had no effect on either
medullary or cortical HO activity in CoPP treated mice. In contrast, administration of QC-13 at a
higher concentration (250 μM) resulted in a significant decrease in both medullary and cortical
HO activity in CoPP treated mice. Systemic administration of QC-13 resulted in significant
decrease both renal cortical and medullary HO activity in CoPP treated mice. In contrast to
classical porphyrin based HO inhibitors, IRMI infusion of QC-13 did not induce HO-1 protein
levels as determined by Western blot analysis of medullary protein samples. Our results
demonstrated that imidazole-dioxolane inhibitors are renal HO inhibitors in vivo and can inhibit
HO activity independent of HO-1 induction. These inhibitors may be useful tools to elucidate the
role of renal HO-1 in numerous physiologic and pathophysiologic conditions.
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Heme oxygenase (HO) is the rate limiting enzyme in the degradation of heme to biliverdin
in which carbon monoxide (CO) is released [1]. Biliverdin is subsequently converted into
bilirubin by biliverdin reductase. The beneficial actions of HO in the cardiovascular system
have been demonstrated by studies in which HO-1 levels were induced either chemically or
genetically. For example, several studies have demonstrated that induction of HO-1 lowers
blood pressure in several rodent models of hypertension [2-5]. Additional studies have
demonstrated that induction of HO-1 protects organs from ischemia-reperfusion injury [6-9].
Whereas HO-1 induction studies have revealed important information regarding the biology
of HO-1, we have also learned much about the biology of HO-1 from inhibitor studies. The
first class of inhibitors and the most widely used are porphyrin compounds. Porphyrins are
ring like structures which can bind to metals and form metalloporphyrins which are potent
HO inhibitors [10,11]. Metallopophyrin based HO inhibitors have been used widely to
elucidate the function of HO-1; however, they have several limitations with their use in vivo.
First, most metalloporphyrins are photosensitive and can breakdown upon exposure to light
which makes working with them difficult [12]. Second, the specificity of these compounds
can be an issue. Several studies have demonstrated that metalloporphyrins can inhibit other
proteins such as nitric oxide synthase and soluble guanylyl cyclase especially when used at
higher concentrations [13-15]. Lastly, while these compounds are inhibitors of HO activity,
they are also very potent inducers of HO-1 due to the metal group associated with the
porphyrin ring [16,17]. Imidazole-dioxolane HO inhibitors are a new class of compounds
which have recently been reported to be specific inhibitors of HO in vitro [18,19]. These
compounds offer a potential advantage in that they do not resemble heme, the natural HO
substrate, and they do not contain metals which may induce HO-1. Recently, the
effectiveness and specificity of imidazole-dioxolane inhibitors was demonstrated in cultures
of proximal tubule cells [20]. Whether these compounds are effective HO inhibitors in the
kidney has yet to be tested. In the present study, we determined for the first time if the




Studies were performed on 16-20 week male C57BL/6J mice (Jackson Labs, Bar Harbor,
ME). All studies were performed in accordance with the approval of the University of
Mississippi Medical Center Institutional Animal Care and Use Committee (IACUC) and in
line with NIH guidelines. Mice were treated with cobalt protoporphyrin (CoPP) as described
below. After seven days, intramedullary interstitial catheters were implanted into the left
kidney and saline infused through the catheter for a period of 2 days. After this time, the
infusion was switched over to QC-13 for an additional 3 days. Mice were then euthanized
for determination of HO activity. Intramedullary interstitial catheters were modified as
previously described [21] and implanted 1.5-2 mm into the left kidney. QC-13 was also
administered by intraperitoneal (ip) injection (52 mg/kg) which is equivalent to 10 times the
25 μM concentration that was administered directly into the renal medulla. In this part of the
study, mice were treated with CoPP as above. After 7 days, mice received single ip
injections of QC-13 for two days and then were euthanized the next day and organs
collected for determination of HO activity.
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dioxolane hydrochloride, was synthesized as previously described [18]. Stock solutions of
QC-13 were prepared in distilled water and diluted in saline for intrarenal medullay
interstitial infusion (IRMI) and ip injections. HO-1 was induced by a single treatment with
CoPP (50 mg/kg body weight, sc, Frontier Scientific, Logan, UT) as previously described
[5].
Heme Oxygenase Assay
Heme oxygenase assay was performed on tissue lysates prepared as previously described
[5]. The protein concentration was measured using a Bio-rad protein assay with BSA
standards. Reactions were carried out in a 1.2 mls containing: 2 mM glucose-6-phosphate,
0.2 units glucose-6-phosphate dehydrogenase, 0.8 mM NADPH, 20 μM hemin, and 0.5 mg
of lysate. The reactions were incubated for 1 hour at 37°C in the dark. The formed bilirubin
was extracted with chloroform, and the change in optical density (ΔOD) at 464-530 nm was
measured using an extinction coefficient of 40 mM/cm for bilirubin. HO activity was
calculated as picomoles of bilirubin formed per hour per milligram of microsomal protein.
For the IRMI studies, HO activity is expressed as percentage of non-infused cortex or
medulla.
Western Blot
Western Blot for HO-1and HO-2 proteins were performed on lysates prepared from the renal
cortex and medulla. Samples of 30 μg of protein were boiled in Laemmli sample buffer
(Bio-Rad, Hercules, CA) for 5 min, electrophoresed on 12% SDS-polyacrylamide gels, and
blotted onto nitrocellulose membrane. Membranes were blocked with Odyssey blocking
buffer (LI-COR, Lincoln, NE) for 2 hours at room temperature, then incubated with mouse
anti-HO-1 antibody (StressGen, Vancouver, Canada, 1:2000) and rabbit anti-β-actin
antibody (abcam, Cambridge, MA, 1:5,000) or rabbit anti-HO-2 polyclonal antibody
(StressGen, Vancouver, Canada, 1:2000) and mouse anti-β actin antibody (abcam,
Cambridge, MA, 1:5,000) overnight at 4°C. The membranes were then incubated with Alexa
680 goat anti-mouse IgG (Molecular Probes, Portland, OR, 1:5,000) and IRDye 800 goat
anti-rabbit IgG (Rockland, Gilbertsville, PA, 1:5,000) or Alexa 680 donkey anti-rabbit IgG
(Molecular Probes, Portland, OR, 1:5,000) or IRDye 800 donkey anti-mouse IgG (Rockland,
Gilbertsville, PA, 1:5,000) for 1 hour at room temperature. The membranes were then
visualized using an Odyssey infrared imager (Li-COR, Lincoln, NE). Experiments were
performed in duplicated and densitometry analysis was performed using Odyssey software
(LI-COR, Lincoln, NE). The level of HO protein is expressed as a ratio to the level of β-
actin to normalize for protein loading.
Statistics
Mean values ± Standard Error (SE) are presented. Significant differences between mean
values were determined using an unpaired T test or by ANOVA followed by a post hoc test
(Tukey). A p<0.05 was considered to be significant.
Results
Effect of Intrarenal Medullary Interstitial Infusion (IRMI) of QC-13 on HO Activity in CoPP
Treated Mice
IRMI infusion of QC-13 at a concentration of 25 μM had no effect on HO activity in the
medulla or cortex of control mice (Figure 1). This result is likely due to the low levels of
HO-1 protein present in the kidney under basal conditions. In order to determine the
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effectiveness of QC-13 in inhibiting HO-1, mice were pre-treated with CoPP which is a
strong inducer of HO-1 protein in vivo [5]. CoPP treatment resulted in a 3 fold increase in
HO activity in both the renal cortex and medulla as compared to control levels (data not
shown). The dose response curves of QC-13 on HO activity in the renal cortex and medulla
of CoPP treated mice are presented in Figure 2. IRMI of QC-13 at a concentration of 2.5 or
25 μM had no effect on renal cortical HO activity. HO activity averaged 106 ± 17 and 111 ±
8% of that observed in the non-infused CoPP treated kidney (Figure 2A). IRMI infusion of
QC-13 at a concentration of 250 μM resulted in a significant decrease in renal cortical HO
activity as compared to the non-infused CoPP treated kidney averaging 59 ± 9% (Figure
2A).
IRMI of QC-13 at a concentration of 2.5 μM had no effect on renal medullary HO activity in
the infused kidney of CoPP treated mice averaging 105 ± 11% (Figure 2B). However, IRMI
of QC-13 at concentrations of 25 and 250 μM resulted in significant decreases in medullary
HO activity in the infused kidney of CoPP treated mice averaging 46 ± 14 and 38 ± 7% of
that observed in the non-infused CoPP treated kidney (Figure 2B).
Effect of Intraperitoneal Injection QC-13 on HO Activity in CoPP Treated Mice
In order to determine the effect of systemic administration of QC-13 on renal HO activity,
CoPP treated mice were treated with two ip injections (52 mg/kg) over a 48 hour period.
Systemic administration of QC-13 at this concentration resulted in a significant decrease in
both renal cortical and medullary HO activity in CoPP treated mice as compared to non-
QC-13 treated mice (Table 1). However, systemic administration of QC-13 at this
concentration did not result in a significant decrease in HO activity in heart or liver of CoPP
treated mice (Table 1).
IRMI Infusion of QC-13 Does Not Induce HO-1 Protein
In order to determine if IRMI infusion of QC-13 was associated with induction of HO-1 or
HO-2 protein, Western blot was performed on lysates from the renal cortex and medulla of
control mice in which QC-13 was infused via intrarenal medullary interstitial catheters as
well as control, IRMI QC-13, CoPP, and CoPP + IRMI QC-13 mice. CoPP treatment
resulted in a 10-fold increase in the level of HO-1 protein in the renal medulla (Figure 3).
IRMI infusion of QC-13 did not induce HO-1 protein either in control or CoPP treated mice
(Figure 3). Next, we determined the effect of IRMI infusion of QC-13 at several
concentrations (2.5, 25, and 250 μM) on the levels of HO-1 and 2 protein in the cortex and
medulla of the infused kidney. IRMI infusion of QC-13 at all concentrations tested had no
effect on the levels of HO-1 or 2 protein in the renal cortex of infused mice (Figure 4).
Likewise, IRMI infusion of QC-13 at all concentrations tested had no effect on the levels of
HO-1 or 2 protein in the renal medulla of infused mice (Figure 5). These results indicate that
unlike porphryrin-based HO inhibitors imidazole-dioxolane inhibitors do not induce HO-1
protein in vivo.
Discussion
The present study is the first to test the efficacy of the imidazole-dioxolane inhibitor, QC-13,
in the in vivo inhibition of HO-1 in the kidney by either direct infusion into the renal
medulla or by systemic administration. Our results demonstrate that when QC-13 was
infused directly into the renal medulla of CoPP treated mice at a concentration of 25 μM
specific inhibition of medullary HO activity was observed. This concentration of QC-13 was
based on the findings of a previous in vitro study which demonstrated that this concentration
of QC-13 resulted in maximal inhibition of HO activity in cultured proximal tubule cells
treated with hemin [20]. While direct medullary infusion of QC-13 at this concentration was
Csongradi et al. Page 4













able to inhibit HO activity in CoPP pretreated mice, no significant inhibition of HO activity
was observed when infused into the renal medulla of control mice. One reason for this
observation may be that under basal conditions HO-1 is expressed at very low levels in the
kidney and the majority of HO activity present may be derived from HO-2 [5,22]. Previous
studies in cultured renal proximal tubule cells have demonstrated that QC-13 is a specific
inhibitor of HO-1 but not HO-2 while another imidazole-dioxolane inhibitor, QC-1, can
inhibit both isoforms of HO [20].
IRMI of QC-13 at a lower concentration (2.5 μM) did not result in inhibition of HO activity
in the renal medulla and cortex of CoPP treated mice. However, IRMI infusion of QC-13 at
a 100 fold higher concentration (250 μM) resulted in significant inhibition of both renal
medullary and cortical HO activity in CoPP treated mice. Classically, compounds that are
infused into the renal medulla are selectively accumulated because of the efficient
countercurrent exchanger in the vasa recta circulation [23]. When compounds are infused at
very high concentrations as with 250 μM QC–13, it is possible that excess accumulation of
the compound increases the amount that gets reabsorbed by the peritubular capillaries
resulting in increased levels of the compounds which are then able to diffuse into the cortex.
Thus, it is important to always test activity in both regions of the kidney when administering
drugs into the renal medullary interstitium to ensure the degree of inhibition in each region.
IRMI infusion at the 25 μM concentration resulted in selective inhibition of renal medullary
but not cortical HO activity. However, we found that systemic administration of QC-13 at
10 at times this concentration inhibited both renal cortical and medullary HO activity
without having any effect on HO activity in the heart and liver. The reason for this
observation is not known but may be due to the increased accumulation of QC-13 in the
kidney upon being filtered from the blood. A portion of the QC-13 could then be reabsorbed
by the tubule cells mainly in the cortex and to a lesser extent in the renal medulla to inhibit
HO activity. QC-13 administered via IP injection at this dose may not have reached a high
enough plasma concentration effectively inhibit HO activity in these organs. While we did
observe a significant decrease in renal cortical and medullary HO activity with this dose of
QC-13, the degree of inhibition was much greater (56%) in the renal cortex as compared to
the medulla (20%). Thus, it may be possible to selectively inhibit medullary versus cortical
HO activity with a lower dose of QC-13 in order to determine the role of HO in these
different regions in various renal pathologies. For example, both renal ischemia and acute
renal injury due to radiocontrast agents are believed to cause preferential damage to the
renal medulla especially thick ascending loop of Henle cells [24,25] while nephrotoxins
such as cisplatin are believed to target proximal tubule cells in the cortex [26,27]. Several
studies have suggested that induction of HO-1 may play a protective role in the response of
the kidney to all of these pathological injuries [28-31]. Differential delivery methods as well
as infusion of different concentrations of the imidazole-dioxolane inhibitor, QC-13, could be
used as a strategy to target either medullary or cortical HO-1 to further investigate the
protective role of HO-1 induction in each of these conditions.
The most widely used class of HO inhibitors are metalloporphyrin based compounds such as
stannous mesoporphyrin, Zinc Deuteroporphyrin IX 2,4 Bis Etylene Glycol (ZnDPBG), and
chromium mesoporphyrin (CrMP) [32-34]. While these compounds can block HO activity,
they are also potent inducers due to the metal containing groups [16,17]. The induction of
HO-1 by these compounds could lead to decreased efficiency of blockade in vivo especially
in situations in which these compounds are administered chronically. Imidazole-dioxolane
inhibitors such as QC-13 offer a distinct advantage over metalloporphyrin based HO
inhibitors in that they do not induce HO-1 in vivo which is less likely to complicate
interpretation of data resulting from their chronic use. They are also water soluble and do
not undergo photosensitization which also makes them easier to chronically infuse in vivo.
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In conclusion, the present study demonstrates that the imidazole-dioxolane inhibitor, QC-13,
is an effective inhibitor of renal HO-1 in vivo. HO-1 activity in the renal medulla or cortex
can be selectively blocked with QC-13 depending upon how the compound is delivered to
the kidney. Systemic administration of QC-13 preferentially inhibits renal cortical HO-1
while direct infusion into the renal medulla at a concentration of 25 μM selectively inhibits
medullary HO-1 activity. Blockade of HO-1 with QC-13 is not associated with induction of
endogenous HO-1 as observed with classical metalloporphyrin based HO inhibitors.
Imidazole-dioxolane HO inhibitors have the potential to be excellent pharmacological tools
to investigate the role of renal HO in a number of different physiological and pathological
processes in the kidney.
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Effect of intrarenal medullary interstitial infusion of QC-13 (25 μM) on renal medullary and
cortical heme oxygenase activity in control mice. QC-13 was infused for two dyas and HO
assays were performed as described in the Methods. HO activity is expressed as the percent
of activity observed in the control non-infused kidney, n=7.
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Dose response curves of intrarenal medullary interstitial infusion of QC-13 (2.5, 25, 250
μM) on A) renal cortical and B) renal medullary heme oxygenase activity in CoPP treated
mice. Mice were administered a single dose of CoPP seven days prior to QC-13 infusion.
QC-13 was then infused for two days and HO assays were performed as described in the
Methods. HO activity is expressed as the percent of activity observed in the non-infused
CoPP treated kidney, n=6. † =statistically different at P <0.004. *= statistically different at
P<0.001.
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Western blot of renal medullary lysates from control, control + intrarenal medullary
interstitial infusion (IRMI) QC-13 (25 μM), CoPP, CoPP + IRMI QC-13 treated mice. A)
Representative blot of HO-1 and β-actin from 30 μg of tissue lysate. B) Quantitation of the
level of HO-1 protein. The level of HO-1 protein is expressed as a ratio to the level of β-
actin, n=3. *=statistically different at p<0.05 by ANOVA followed by a post hoc test
(Tukey).
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Western blot of renal cortical HO-1 and HO-1 proteins from QC-13 infused mice. A)
Representative blots of HO-1, HO-2, and β-actin from the renal cortex of QC-13 treated
mice. QC-13 was infused via intrarenal medullary interstitial catheters for two days after
which time kidneys were collected for protein measurements. B) Quantitation of the level of
HO-1 protein. The level of HO-1 protein is expressed as a ratio to the level of β-actin, n=4.
C) Quantitation of the level of HO-2 protein. The level of HO-2 protein is expressed as a
ratio to the level of β-actin, n=4.
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Western blot of renal medullary HO-1 and HO-1 proteins from QC-13 infused mice. A)
Representative blots of HO-1, HO-2, and β-actin from the renal medulla of QC-13 treated
mice. QC-13 was infused via intrarenal medullary interstitial catheters for two days after
which time kidneys were collected for protein measurements. B) Quantitation of the level of
HO-1 protein. The level of HO-1 protein is expressed as a ratio to the level of β-actin, n=4.
C) Quantitation of the level of HO-2 protein. The level of HO-2 protein is expressed as a
ratio to the level of β-actin, n=4.
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Table 1
Effect of intraperitoneal injection of QC-13 (52/mg/kg) on HO activity in CoPP Treated Mice.
Heme Oxygenase Activity
Organ CoPP CoPP + QC-13
Heart 35+ 15 24+ 7
Liver 250 + 64 195 + 26
Renal Cortex 219 + 38 98 + 27*
Renal Medulla 51 + 6 41 + 2*
Heme oxygenase activity given as pmoles bilirubin per hr per milligram of protein.
*
p<0.05 as compared to CoPP treated mice. n=6 per group.
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